Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared to Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study
Conclusions Z-215 was as effective and well-tolerated as 10 mg RPZ in the treatment of RE in this selected population. CYP2C19 genotype status may not affect the efficacy and safety of Z-215. There were no clear dose-response effects between Z-215 doses in the endoscopic healing of RE. These findings suggest that Z-215 may be one option for the initial treatment of RE. (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - March 23, 2018 Category: Drugs & Pharmacology Source Type: research
Drugs for GERD and Peptic Ulcer Disease
Date: January 15, 2018
Issue #:
1538Summary:
Gastroesophageal reflux disease (GERD) is the most
frequent GI condition encountered in the outpatient
setting; it affects about 20% of the US population.
Heartburn and regurgitation are the classic symptoms
of GERD. (Source: The Medical Letter)
Source: The Medical Letter - November 29, 2017 Category: Drugs & Pharmacology Authors: admin Tags: Aciphex alginate Alinia Amoxicillin Amoxil Antibacterials Arthrotec Aspirin Axid Biaxin Bismuth subsalicylate Calcium supplements Carafate Cimetidine Clarithromycin Coumadin Cytotec Dexilant Dexlansoprazole Diclofenac Source Type: research
Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers.
Abstract
The pharmacokinetics (PK) and pharmacodynamics (PD) of proton pump inhibitors differ among cytochrome P450 (CYP) 2C19 genotypes. Therefore, we developed azeloprazole sodium (Z-215), a novel proton pump inhibitor, whose metabolism is not affected by CYP2C19 activity in vitro. However, the PK and PD of azeloprazole sodium have not been evaluated in Japanese subjects. We conducted an open-label, crossover study in healthy Japanese male volunteers to evaluate the plasma concentration and intragastric pH with respect to CYP2C19 genotype after repeated administration of 10, 20, and 40 mg azeloprazole s...
Source: The Journal of Clinical Pharmacology - November 28, 2017 Category: Drugs & Pharmacology Authors: Toda R, Shiramoto M, Komai E, Yoshii K, Hirayama M, Kawabata Y Tags: J Clin Pharmacol Source Type: research
In Brief: PPIs and Torsades de Pointes
Date: December 5, 2016
Issue #:
1509Summary:
Therapeutics (AZCERT) has recently added the proton pump inhibitors (PPIs) omeprazole (Prilosec, and others), esomeprazole (Nexium, and others), lansoprazole (Prevacid, and others), and pantoprazole (Protonix, and generics) to its lists of Drugs with Conditional Risk of Torsades de Pointes (TdP) and Drugs to Avoid in Patients with Congenital Long QT Syndrome.1PPIs do not directly cause prolongation of the QT interval, but they can cause hypomagnesemia, which is often accompanied by hypocalcemia and hypokalemia and can result in cardiac...
Source: The Medical Letter - November 2, 2016 Category: Drugs & Pharmacology Authors: admin Source Type: research
Do proton pump inhibitors cause dementia?
A great deal of media attention has been given to a recently-published study that concluded that the prevalence of dementia was significantly greater in patients who had been regularly taking a proton pump inhibitor (PPI) including omeprazole (Prilosec), esomeprazole (Nexium), lansoprazole (Prevacid), pantoprazole (Protonix) or rabeprazole (Aciphex). The article was reported by many media outlets in stories with titles ranging from “Can Common Heartburn Drugs Raise Risk for Dementia?” and “Proton Pump Inhibitors Linked to Dementia” the former being a title that perhaps distorts the actual study findings misleading ...
Source: Geriatric Nursing - May 1, 2016 Category: Nursing Authors: William Simonson Tags: Department Source Type: research
Development and validation of dissolution testings in acidic media for rabeprazole sodium delayed-release capsules.
Authors: Tan Y, Si X, Zhong L, Feng X, Yang X, Huang M, Wu C
Abstract
Rabeprazole sodium (RAB) dissolved in acidic media is accompanied by its degradation in the course of dissolution testing. To develop and establish the accumulative release profiles of ACIPHEX(®) Sprinkle (RAB) delayed-release capsules (ACIPHEX(®) Sprinkle) in acidic media using USP apparatus 2 (paddle apparatus) as a dissolution tester, the issues of determination of accumulative release amount of RAB in these acidic media and interference of hydroxypropylmethyl cellulose phthalate were solved by adding appropriate hydrochloric acid (...
Source: Drug Development and Industrial Pharmacy - April 15, 2016 Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research
Stomach specific polymeric low density microballoons as a vector for extended delivery of rabeprazole and amoxicillin for treatment of peptic ulcer
In conclusion, greater compatibility, higher gastro-retention and higher anti-ulcer activity of the presently fabricated formulations to improve potential of formulation for redefining ulcer treatment are presented here. These learning exposed a targeted and sustained drug delivery potential of prepared microballoons in gastric region for ulcer therapeutic intervention as corroborated by in vitro and in vivo findings and, thus, deserves further attention for improved ulcer treatment. Graphical abstract (Source: Colloids and Surfaces B: Biointerfaces)
Source: Colloids and Surfaces B: Biointerfaces - February 12, 2016 Category: Biochemistry Source Type: research
Development and validation of HPLC-DAD method for the simultaneous determination of amoxicillin, metronidazole and rabeprazole sodium. Application to spiked simulated intestinal fluid samples.
Abstract
This work deals with the development, validation and application of an HPLC-DAD method for the determination of a ternary mixture containing amoxicillin (AX), metronidazole (MZ) and the proton pump inhibitor rabeprazole sodium (RB). This triple therapy is used for treatment of Helicobacter pylori infection. Effective chromatographic separation between the three drugs was achieved using Thermo Hypersil BDS-C8 (4.6×250mm, 5μm particle size) column and a mobile phase composed of phosphate buffer pH 7 and acetonitrile (70: 30, by volume). The mobile phase was pumped isocratically at a flow rate of 1...
Source: Annales Pharmaceutiques Francaises - May 26, 2015 Category: Drugs & Pharmacology Authors: Sabry SM, Abdel-Hay MH, Belal TS, Mahgoub AA Tags: Ann Pharm Fr Source Type: research
Applications of simultaneous equation method and derivative method for the determination of rabeprazole sodium and levosulpiride in pharmaceutical dosage form and dissolution samples
Publication date: April 2014 Source:Journal of the Association of Arab Universities for Basic and Applied Sciences, Volume 15 Author(s): Poornima R. Shetty , Dipak D. Patil Two simple, accurate, precise, economical procedures, entailing neither irksome sample treatment nor tedious extraction process have been developed for the simultaneous estimation of rabeprazole sodium and levosulpiride in combined tablet dosage form. The first method was based on employing simultaneous equation method for analysis of both drugs. Rabeprazole sodium and levosulpiride have shown absorbance maxima at 284 and 232nm in methanol, respec...
Source: Journal of the Association of Arab Universities for Basic and Applied Sciences - November 3, 2014 Category: Science Source Type: research
Stability-indicating HPLC–DAD methods for determination of two binary mixtures: Rabeprazole sodium–mosapride citrate and rabeprazole sodium–itopride hydrochloride
Publication date: August 2014 Source:Journal of Pharmaceutical Analysis, Volume 4, Issue 4 Author(s): Hamed M. El-Fatatry , Mokhtar M. Mabrouk , Ismail I. Hewala , Ehab H. Emam Two selective stability-indicating HPLC methods are described for determination of rabeprazole sodium (RZ)–mosapride citrate (MR) and RZ–itopride hydrochloride (IO) mixtures in the presence of their ICH-stress formed degradation products. Separations were achieved on X-Bridge C18 column using two mobile phases: the first for RZ–MR mixture consisted of acetonitrile: 0.025M KH2PO4 solution: TEA (30:69:1 v/v; pH 7.0); the second for RZ–...
Source: Journal of Pharmaceutical Analysis - November 3, 2014 Category: Drugs & Pharmacology Source Type: research
Population Pharmacokinetics of Rabeprazole and Dosing Recommendations for the Treatment of Gastroesophageal Reflux Disease in Children Aged 1–11 Years
Conclusions
The pharmacokinetics of rabeprazole were described with good precision following administration of rabeprazole across a range of doses and in a range of formulations. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - September 25, 2014 Category: Drugs & Pharmacology Source Type: research
The chiral bioconversion and preclinical pharmacokinetic analysis of (R)-(+)-rabeprazole in beagle dogs by HPLC and HPLC-MS/MS.
Abstract
In order to accurately investigate the preclinical pharmacokinetics of (R)-(+)-rabeprazole sodium injection, a reliable high-performance liquid chromatography (HPLC) method was developed using a Chiral-AGP column to prove that there is no chiral bioconversion of (R)-(+)-rabeprazole to (S)-(-)-rabeprazole in beagle dogs after single intravenous administration of (R)-(+)-rabeprazole sodium injection. An HPLC-tandem mass spectrometry (HPLC-MS/MS) method for analysis of (R)-(+)-rabeprazole was developed and validated, and used to acquire the pharmacokinetic parameters in beagle dogs. (R)-(+)-Rabeprazo...
Source: Biomedical Chromatography : BMC - May 22, 2013 Category: Biomedical Science Authors: Gao YH, Xu JX, Su ZX, Song L, Lou HX Tags: Biomed Chromatogr Source Type: research
Classification of chronic cough by systematic treatment cascade trial starting with beta agonist
Conclusions:
The majority of chronic cough was BRC. NHBRC was a new chronic cough entity. GERD is a common cause of chronic cough in Japan, as in Western countries. AC and SBS are also causes of chronic cough in Japan.Trial registration: University hospital medical information network (UMIN 000007483). (Source: Cough)
Source: Cough - February 7, 2013 Category: Respiratory Medicine Authors: Hideyasu ShimizuMasamichi HayashiYuji SaitoYuki MienoYasuo TakeuchiFumihiko SasakiHiroki SakakibaraKensei NaitoMitsushi Okazawa Source Type: research
